NCT04676906View on ClinicalTrials.gov

A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 26, 2020

Primary Completion Date

April 28, 2021

Study Completion Date

April 28, 2021

Conditions
Healthy VolunteersType 2 Diabetes
Interventions
DRUG

NNC0113-6861

Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861

DRUG

NNC0113-6860

Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860

DRUG

NNC0113-6891

Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY